Peak Financial Advisors LLC Takes Position in Zoetis Inc. (NYSE:ZTS)

Peak Financial Advisors LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 14,067 shares of the company's stock, valued at approximately $2,776,000. Zoetis makes up 1.9% of Peak Financial Advisors LLC's portfolio, making the stock its 12th largest holding.

Several other hedge funds also recently added to or reduced their stakes in ZTS. Strategic Investment Advisors MI bought a new stake in shares of Zoetis during the 4th quarter worth about $280,000. Seneca House Advisors boosted its position in Zoetis by 0.3% during the fourth quarter. Seneca House Advisors now owns 24,208 shares of the company's stock valued at $4,778,000 after purchasing an additional 82 shares during the last quarter. GuoLine Advisory Pte Ltd lifted its position in shares of Zoetis by 25.0% in the fourth quarter. GuoLine Advisory Pte Ltd now owns 174,400 shares of the company's stock worth $34,421,000 after buying an additional 34,900 shares during the last quarter. Arthur M. Cohen & Associates LLC lifted its position in shares of Zoetis by 7.7% in the fourth quarter. Arthur M. Cohen & Associates LLC now owns 4,999 shares of the company's stock worth $987,000 after buying an additional 359 shares during the last quarter. Finally, Enterprise Bank & Trust Co acquired a new stake in shares of Zoetis in the fourth quarter worth about $210,000. 89.47% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business's stock in a transaction that occurred on Thursday, January 18th. The stock was sold at an average price of $191.43, for a total transaction of $176,689.89. Following the transaction, the executive vice president now owns 17,569 shares of the company's stock, valued at approximately $3,363,233.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have sold 2,209 shares of company stock valued at $408,453. 0.12% of the stock is owned by insiders.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of analyst reports. Stifel Nicolaus boosted their price target on Zoetis from $195.00 to $215.00 and gave the stock a "buy" rating in a research report on Friday, January 12th. BNP Paribas began coverage on Zoetis in a research report on Thursday, December 7th. They issued an "outperform" rating and a $237.00 price target for the company. The Goldman Sachs Group boosted their price objective on Zoetis from $190.00 to $226.00 and gave the stock a "buy" rating in a research report on Wednesday, January 17th. Piper Sandler boosted their price objective on Zoetis from $215.00 to $220.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 20th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $224.33.

Zoetis Price Performance

Shares of ZTS stock traded down $1.90 during trading hours on Monday, hitting $170.67. 4,954,613 shares of the company's stock were exchanged, compared to its average volume of 2,622,553. The stock's 50-day moving average is $190.23 and its 200-day moving average is $183.33. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. The stock has a market cap of $78.14 billion, a price-to-earnings ratio of 34.11, a price-to-earnings-growth ratio of 2.65 and a beta of 0.87. Zoetis Inc. has a 52 week low of $151.03 and a 52 week high of $201.92.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. Zoetis's revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.15 EPS. As a group, research analysts forecast that Zoetis Inc. will post 5.8 EPS for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 1.01%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis's dividend payout ratio is presently 34.12%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.